[1] An example of MAB is the combination of bicalutamide, an AR antagonist, with a gonadotropin-releasing hormone (GnRH) analogue such as leuprorelin or cetrorelix.
[1] MAB was developed for and is employed in the treatment of prostate cancer.
[1] Triple androgen blockade (TrAB) is a method of ADT in which a 5α-reductase inhibitor such as finasteride or dutasteride is added to CAB.
[2][3] MAB has been found to produce higher rates of gynecomastia (7 to 28%) than orchiectomy and GnRH analogues alone (1 to 16%), but lower rates than nonsteroidal antiandrogen monotherapy such as with bicalutamide (30 to 85%).
This drug article relating to the genito-urinary system is a stub.